IDXX - Company ID 0000874716
IDEXX LABORATORIES INC /DE trades as IDXX and has a market capitalization of $44.06 B, making it the #358 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.30B, up 10.4% from the prior year and net income of $1.06B. This page tracks IDEXX LABORATORIES INC /DE through 2,148 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years IDEXX LABORATORIES INC /DE's revenue grew from $1.78B to $4.30B, a compound annual growth rate of 10.3%. Net profit margin expanded from 12.5% to 24.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-20 |
| Major company event | 8-K | 2026-05-15 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 compared to prior guidance midpoint, supported by expectations for ...
Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million, reflecting growth of 7.6% - 9.6% reported and 7.0% ...
Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including operating margin expansion of 100 basis points as ...
The largest companies sharing IDEXX LABORATORIES INC /DE's SEC industry classification (in vitro & in vivo diagnostic substances).
IDEXX LABORATORIES INC /DE (IDXX) has a market capitalization of $44.06 B as of 2026-07-09, ranking #358 among US-listed companies.
IDEXX LABORATORIES INC /DE reported revenue of $4.30B for fiscal year 2025, an increase of 10.4% year over year.
Yes. IDEXX LABORATORIES INC /DE reported net income of $1.06B in its latest fiscal year.